Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B-cell hyperreactivity. The Toll-like receptor 7 (TLR7) signaling pathway is abnormally activated in SLE B cells. CyclinD3 (CCND3) plays an important role in B-cell proliferation, development, and differentiation. Although previous studies focused on the B cell-intrinsic role of TLR7 for the development of spontaneous germinal centers, the influence of TLR7 on CCND3 in SLE B cells is still not clear. Here, we used a B-cell profiling chip and found that CCND3 was related to SLE and significantly elevated in SLE B cells. Moreover, we determined that the expression level of CCND3 was higher, while miR-15b was significantly lower in the B cells from SLE patients and B6.MRL-Faslpr/J lupus mice compared to normal subjects. Furthermore, we demonstrated that the activation of TLR7 dramatically increased CCND3 expression but significantly decreased miR-15b in B cells in vitro and we identified that CCND3 is a direct target of miR-15b. To further confirm our results, we established another lupus model by topically treating C57BL/6 (B6) mice with the TLR-7 agonist imiquimod (IMQ) for 8 weeks according to the previously described protocol. Expectedly, topical treatment with IMQ also significantly increased CCND3 and decreased miR-15b in B cells of B6 mice. Taken together, our results identified that the activation of TLR7 increased CCND3 expression via the downregulation of miR-15b in B cells; thus, these findings suggest that extrinsic factor-induced CCND3 expression may contribute to the abnormality of B cell in SLE. Cellular & Molecular Immunology
INTRODUCTION
Systemic lupus erythematosus (SLE) is a typical human autoimmune disease that is characterized by the loss of tolerance to nuclear self-antigens and the production of pathogenic autoantibodies. 1 Germinal centers (GCs) are important sites of immunoglobulin (Ig) class switching and antibody affinity maturation, and experimental evidence has indicated that it is the main site for generating high-affinity antibody-secreting plasma cells and memory B cells. 2 Spontaneous formation of GCs 3 and abnormal B-cell differentiation in GCs are associated with the development of SLE in both humans and murine models. 4, 5, 6 CyclinD3 (CCND3) plays a very important and unique role in the development of a B cell in the special microenvironment of GCs. 7, 8 CCND3 is one of the three D-type (D1, D2, and D3) cyclins that regulate the G1/S phase transition of the cell cycle. 9, 10 Experiments from CCND3 2/2 mice demonstrated that CCND3 is required for the transition from a pro-B cell to a large pre-B cell. 11 Therefore, abnormal expression of CCND3 is associated with many diseases. 12, 13, 14 However, to date, there is no evidence to confirm the abnormality of CCND3 in SLE.
Toll-like receptors (TLRs) detect microbial components that play fundamental roles in the induction of immune responses, 15 and B cell-intrinsic TLR signaling is very important for the development and activation of B cells. 16 Recently, it has become apparent that TLR7, which senses single-stranded RNA, plays a pivotal role in the development of SLE in murine models. 17 For example, deletion of a single TLR7 allele in lupus-prone mice leads to an increased elimination of anti-RNA autoantibodies and significant alleviation of disease symptoms. 18 Genetic overexpression of X-linked genes, as observed in mice carrying the Y-linked autoimmune accelerator lupus susceptibility locus including TLR7, has also been strongly associated with lupus disease development. 19, 20, 21, 22, 23 Of note, topical treatment of wild-type mice with TLR7 agonists leads to lupus-like autoimmunity in several strains of mice. 10 In addition, previous studies have focused on the effect of B cell-intrinsic TLR7 signaling on immune activation, autoantibody repertoire, systemic inflammation, 18, 24 and the development of GCs. 25, 26 Although TLR7 and abnormal GC B cells have been associated with SLE disease in human and mice, and CCND3 is indispensable for GC B cells formation, the influence of TLR7 on the expression of CCND3 in B cell remains unclear.
MicroRNAs (miRNAs) are a class of noncoding, small RNAs that modulate gene expression at the post-transcriptional level. 27 Mounting evidence has demonstrated that miRNAs play a vital role in autoimmunity. 28 Some miRNAs, such as miR-30a, miR-155, miR-146a, and miR-181a, have been shown to be involved in the pathogenesis of SLE. 29, 30 Moreover, miRNA profiles demonstrated that miR-15a, miR15b, and miR-16 were downregulated in the peripheral blood mononuclear cells (PBMCs) of active SLE. 31, 32 However, little is known about the potential roles of these three miRNAs in SLE development and progression.
In this study, we have used a B-cell profiling chip and identified that CCND3 was a hub node in SLE B cell gene network. We also found higher CCND3 and lower miR-15b expression levels in B cells from both SLE patients and lupus mice. Moreover, the activation of TLR7 increased CCND3 expression but decreased miR-15b level in B cells in vitro. Furthermore, we identified CCND3 was a direct target gene of miR-15b. Consistently, we found that the topical treatment of B6 mice with the TLR7 agonist imiquimod (IMQ) significantly downregulated the expression of miR-15b while upregulating CCND3 in mouse B cells. Together, our results showed that the activation of TLR7 increased CCND3 expression via the downregulation of miR-15b in B cells, suggesting that extrinsic factor-induced CCND3 expression may contribute to B-cell abnormality in SLE.
MATERIALS AND METHODS

Human samples
All subjects gave written informed consent prior to enrolment in the study, which was approved by the Nanjing University Research Ethics Committee. For the microarray analysis, five female healthy subjects (mean age 30 6 6 years) were recruited from a local blood bank and five female patients diagnosed with active SLE (mean age 30 6 7 years) were recruited for whole blood samples (50 mL) from Nanjing Drum Tower Hospital. All of the SLE patients were diagnosed according to the revised criteria issued by the American College of Rheumatology in 1997. Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) and the cut-off for active disease classification was decided to be o8. For real-time PCR verification, whole blood samples from independent female were obtained; five healthy subjects (mean age 35 6 6 years) and five active SLE patients (mean age 32 6 9 years) were enrolled. The details of the SLE patients are summarized in Supplementary Table 1 . To exclude drug influence on gene expression, all SLE medications were withheld 24 h before blood sampling.
Mice Female C57BL/6 and sex and age-matched B6.MRL-Fas lpr /J lupus-prone mice were obtained from the Model Animal Research Center of Nanjing University (Nanjing, China) and were kept in specific pathogen-free (SPF) conditions. The Nanjing University Animal Care Commission approved all manipulations. For lupus model induction, 7-to 8-week-old female C57BL/6 mice were topically treated with 5% IMQ cream (3M Health Care, St. Paul, MN, USA) for 2 months as described previously. 10 RNA isolation and microarray data analysis TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from the obtained B cells according to the manufacturer's instructions. Total RNA quality was assessed by Nanodrop 2000 spectrophotometry (Thermo Fisher, Waltham, MA, USA). Only samples with a total RNA concentration .1 mg/mL and a 260 nm/280 nm optical density ratio between 1.8 and 2.0 were submitted for double-stranded cDNA synthesis. Then, the cDNA was labeled with the NimbleGen One-Color DNA Labeling Kit according to the manufacturer's instruction (Roche, Basel, Switzerland). The labeled cDNA was hybridized with a NimbleGen 123135K Human Gene Expression Microarray (Roche, Basel, Switzerland). Following hybridization, the microarray slides were scanned with the Roche-NimbleGen MS200 confocal laser scanner (Roche, Basel, Switzerland). Sequentially, NimbleScan software (version 2.5) was used to analyze the obtained images. All gene level files were imported into Agilent GeneSpring GX software for further analysis. The normalized ratios of the gene expression signals were log2 transformed, and hierarchical clustering was performed with average linkage. Then, the clustered heat map was visualized using Treeview.
Hierarchical cluster, GO term, GO trees, pathways, and protein-protein interaction (PPI) network construction To assess the potential biological significance of the changes observed on the microarrays, gene ontology (GO) analysis was performed using 1476 differentially expressed genes (DEGs) between SLE patients and healthy controls. The significant GO term was selected with a P value , 0.01. Additionally, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was conducted on the significantly changed genes in unique patterns, and the significant KEGG pathways with P value , 0.05 were selected. GO trees were visualized for interpreting interesting gene sets using GO hierarchies, and the GO term with P value , 0.05 were chosen. The PPI network was used to elucidate the interactions among the genes. Based on the latest version of the KEGG database, the networks were built among those DEGs. In the PPI network, a hub node was defined as the node that has the highest number of interactions with other nodes. PPI networks were visualized using Cytoscape software, which is an open source software for integrating molecular states with biomolecular interaction networks and high-throughput expression data into a unified conceptual framework.
B-cell isolation and culture
Human B cells were isolated using human CD19
1 B-Cell isolation beads as described previously. 33 Spleen B cells from mice were obtained by mouse CD45R (B220) MicroBeads according to the manufacturer's procedure. Mouse B cells were cultured in 96-well flat-bottom plates (Corning) at a density of 1 3 10 6 / mL in RPMI1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% FBS (Gibco, Grand Island, NY, USA) and antibiotics (penicillin 100 mg/mL, streptomycin 10 mg/mL; Invitrogen, Carlsbad, CA, USA) at 37uC in a humidified atmosphere of 5% CO 2 . For stimulation treatment, B cells were stimulated with R848 (1 mg/mL, Enzo Life Science, Farmingdale, NY, USA), interferon-a (IFN-a) (1000 U/mL, eBioscience, San Diego, California, USA), AffiniPure F(ab9) 2 Fragment Goat Anti-Mouse IgM (5 mg/mL, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA), or control medium.
Quantitative real-time PCR TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA according to the manufacturer's instructions. All real-time PCR assays were performed on a 7300 qRT-PCR System (ABI) using SYBR green dye (Invitrogen, Carlsbad, CA, USA) with U6 or GAPDH serving as an endogenous control. The relative messenger RNA (mRNA) quantification expression of the genes was calculated using the 2 2DDCT formula. The values reported are the mean of at least three technical replicates. The sequences of RT-PCR primer sets are listed in Supplementary Table 3 .
Construction of plasmids
Mouse genomic DNA served as a template to amplify the CCND3 39 untranslational region (39-UTR), which contains the putative binding sites of miR-15b. The amplified polymerase chain reaction product was gel-purified, digested with XbaI, and inserted into the XbaI sites of the PGL3 vector (GENEray Biotechnology, Shanghai, China); thus, producing PGL3-CCND3-39-UTR.
Transient transfection and reporter assay
The cell line L929 was purchased from the Shanghai Institute of Cell Biology (Shanghai, China). Negative control (NC) miRNA and miR-15b mimic were purchased from Gene Pharma (Shanghai, China). L929 cells were cultured in 6-well plates in a medium without antibiotics at a concentration of 1 3 10 5 /mL for approximately 24 h before transfection. L929 cells were transiently transfected with the NC or miR-15b mimic with a final concentration of 20 nM or 40 nM using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). After 6-h incubation at 37uC and 5% CO 2 , the medium was replaced with fresh culture medium. L929 cells were co-transfected with NC or miR-15b mimic at a final concentration of 20 nM and wild-type 39-UTR of CCND3. Cells were collected 24 h later, and the luciferase activity was assayed using a dual-luciferase assay system (Promega, Wisconsin, WI, USA).
Western blot
The cells were lysed in an ice-cold buffer containing10 mM TrisHCl (pH 7.3), 150 mM NaCl, 2 mM Na 3 VO 4 , 0.4 mM EDTA, 10 mM NaF, 1 mM PMSF, 5 mg/mL of aprotinin and leupeptin and 1% NP-40. Total lysates were resolved by 10% SDS-PAGE and transferred to nitrocellulose. CyclinD3, b-Actin, and GAPDH were detected using primary antibodies (Cell Signaling Technology, Danvers, MA, USA) followed by an HRP-conjugated anti-mouse secondary antibody (Cell Signaling Technology, Danvers, MA, USA). The densitometry software Quantity One v4.62 was used for protein expression analysis.
Flow cytometry
Spleen cells were obtained from either IMQ-treated or control mice. The cells were stained according to the manufacturer's instructions, and the stained cells were analyzed using a BD FACSCalibur cytometer. The following Abs were used: B220-FITC, CD69-PE, CD138-PE, CD19-PE, GL7-FITC, CD95-APC, CD3-Pecy5.5 and CD138-PE from eBioscience. The data were analyzed using Flow Jo software (Tree Star, San Carlos, CA, USA). B220
1
CD95
1 GL7 1 GC B cells and B220 2 CD95 2 GL7 2 non-GC B cells were sorted using BD FACS Aria II.
Hematoxylin and eosin (HE) staining
For histopathological analysis, kidney segments were fixed in 10% buffered formalin phosphate, and paraffin-embedded sections (4 mm) were prepared for HE staining (Beyotime, Shanghai, China).
Statistical analysis
The results were represented as the means 6 SEM. All experiments were repeated at least three times. One-way ANOVA followed by the Student-Newman-Keuls multiple comparisons tests were used to analyze the statistical significance between the groups, and P value , 0.05 was considered statistically significant. Graphics were built using GraphPad prism software (www.graphpad.com).
RESULTS
Sample clustering of differential gene expression profiling of CD19
1 B cells To explore candidate genes related to SLE in B cells, a microarray-based gene expression profiling of CD19 1 B cells was conducted between five active SLE patients and five healthy donors. Hierarchical cluster analysis was applied for the chan- ged genes with a fold-change . 1.5 (P , 0.05, FDR , 30%) or a fold-change , 0.667 ( Figure 1a) . Expectedly, the 10 samples were categorized into two main distinct clusters, and 1812 genes were significantly different in the SLE groups compared to the healthy groups. Of those, 958 genes were upregulated while 854 genes were downregulated (Supplementary Table 2 ).
To verify the data obtained from the microarray, eight selected DEGs (four upregulated and four downregulated) were examined by real-time PCR based on their involvement in different functional groups and/or pathways. Our results showed that the investigated genes had congruent results between realtime PCR and the microarray assays (Figure 1b) . The primers used for the genes are summarized in Supplementary Table 3 .
Gene ontology (GO) term and GO tree analysis To determine the key DEGs participating in cellular behavior and signaling pathways in SLE, an analysis of GO enrichment was conducted (Supplementary Figure 1a) . Many of these DEGs were enriched in inflammation (e.g., type I interferonmediated signaling pathway and cytokine-mediated signaling pathway) and the cell cycle (e.g., M phase of mitotic cell cycle and mitotic cell cycle). All significant GO terms of DEGs and related data are summarized in Supplementary Table 4 . GO tree analysis is very useful to facilitate comparisons of multiple GO analysis results, which can provide valuable insights for biological interpretation. To further investigate the hierarchical classification between those GO terms, GO trees were constructed for the GOs terms that had a P value , 0.05 (Supplementary Figure 1b) . In summary, the upregulated genes mainly influenced the cell cycle and the downregulated genes mainly influenced cell differentiation. Thus, these data suggest that cell cycle-and cell differentiation-related DEGs appeared to be the most enriched GO terms involved in the molecular network during the pathogenesis of SLE.
GO pathway and protein-protein interaction network analysis
The significant KEGG pathways were selected based on the threshold of a P value , 0.05. The significant pathways of upregulated DEGs that were mainly enriched included the cell , and CCR5 were upregulated; SCOS3, HLA-DOB, KLF4, and ID3 were downregulated in the SLE group compared with the healthy control group (left). To validate the microarray analysis findings, we analyzed the mRNA expression using real-time PCR (right) in independent normal (n 5 5) and SLE patient (n 5 5) samples. Each bar represents the mean 6 SEM. *P value , 0.05, **P value , 0.05, ***P value , 0.001.
cycle and biosynthesis of unsaturated fatty acids signaling pathways, while the significant pathways of downregulated DEGs mainly included SLE and protein digestion and absorption pathways (Figure 2a) . The DEGs involved in significant pathways are listed in Supplementary Table 5 .
Genes do not function in isolation but as interacting partners in complex molecular networks that influence biological processes. Protein interaction network analysis is useful to identify the key genes in those networks. Based on the latest version of the KEGG database, we employed protein interaction network analysis, and gene networks were conducted according to their direct or indirect contact among these DEGs using the Cytoscape software. In this study, we constructed a protein interaction network and found that CCND3 was a hub gene among upregulated genes in the network map. Other DEGs in the network were indirectly or directly associated with CCND3 (Figure 2b ), suggesting that it plays important roles in the development of SLE.
CCND3 expression is elevated in B cells from both SLE patients and lupus-like mice To confirm the results of the protein interaction network analysis, we examined the mRNA expressions level of CCND3 in human samples and mouse models. Real-time PCR was performed between five healthy controls and five SLE patients. The results showed that the mRNA level of CCND3 was significantly higher in the SLE patient samples than in the normal samples (Figure 3a) . Additionally, the real-time PCR results showed that CCND3 expression levels were higher in spleen B cells from B6.MRL-Fas lpr /J mice than from C57BL/6 mice ( Figure 3b ). Consistent with the mRNA level, the protein levels of CCND3 were also significantly enhanced in spleen B cells from B6.MRL-Fas lpr /J mice (Figure 3c and d) .
Activation of TLR7 elevates CCND3 expression but decreased the expression of miR-15b in B cells
Our previous work 33 and other research showed that IFNa, B-cell receptor (BCR) and TLR7 signaling pathways play critical roles in the pathogenesis of lupus. 18, 34, 35 To determine whether activation of those pathways could affect CCND3 expression in B cells, we stimulated mouse B cells with IFN-a (1000 U/mL), anti-IgM (5 mg/mL) or TLR7 agonist R848 (1 mg/mL) for 6 h or 24 h. Compared with the control, B cells treated with R848 showed a significant increase in the expression of CCND3 in a time course experiment, while treatment with IFN-a or anti-IgM did not show any significant difference (Figure 4a ). The protein expression results were consistent with the transcriptional results (Figure 4b ). Previous miRNA profiles have demonstrated that miR-15a, miR-15b, and miR-16 are downregulated in the PBMC of active SLE. 31, 32 These miRNAs belong to the miR-15 precursor family that also includes miR-195 and miR-497. Additionally, the miR-15 precursor family is one of the miRNA families that could regulate CCND3 as predicted by Targetscan software. First, we determined the expression levels of these miRNAs from miR-15 precursor family in mouse B cells. The expression of miR-15b was approximately twofold higher than those (1 mg/mL) for 6 h and real-time PCR was performed to detect the expression level of miR15a, miR-15b, and miR-16. All data are representative of three independent experiments, and each bar represents the mean 6 SEM. **P value , 0.01, ***P value , 0.001, ns, no significant difference. One of at least three reproducible experiments is shown.
of miR-15a and miR-16, as determined by real-time PCR (Figure 4c ), while the levels of miR-195 and miR-497 were very low. Then, we examined whether treatment of B cells with R848 could downregulate the expression of these miRNAs. Because the levels of miR-195 and miR-497 were very low, we did not examine the levels of these two miRNAs. We detected the expression level of miR-15a, miR-15b, and miR-16 after treatment of B cells with R848 (1 mg/mL) for 6 h (Figure 4d ). The real-time PCR results showed that the expression levels of these three miRNAs were significantly decreased after treatment with R848. Collectively, these data suggest that miR-15b is the predominantly downregulated miRNA of the miR-15 family in B cells treated with R848.
miR-15b is decreased in B cells from both SLE patients and lupus-like mice To validate whether miR-15b expression is decreased in B cells from active SLE and B6.MRL-Faslpr/J lupus mice, we tested the miR-15b level in both human and mouse samples. Consistent with our in vitro findings, the expression level of miR-15b was significantly decreased in B cells of SLE PBMC and female B6.MRL-Faslpr/J mice (Figure 5a and b) . These data suggested that miR-15b may be involved in the regulation of CCND3 expression.
CCND3 is a direct target of miR-15b
Confirming that CCND3 was a direct target of miR-15b, overexpression of synthetic miR-15b significantly inhibited CCND3 mRNA and protein expression levels in L929 cells (Figure 6a and b) . Furthermore, the 39-UTR of CCND3 that contains the putative sites for miR-15b were amplified and introduced downstream of the luciferase reporter gene in the XbaI-cloning sites of the pGL3 control vector. The luciferase activity assay showed that miR-15b significantly mimicked the PGL3-CCND3-39-UTR luciferase activity in L929 cells (Figure 6c ). Taken together, these results confirmed that miR-15b directly targets CCND3.
Downregulated miR-15b and upregulated CCND3 are confirmed in the B cells of an imiquimod-induced lupus-like model IMQ, similar to R848, is another synthetic imidazoquinoline TLR7 compound ligand and is also referred to as R-837. 36, 37 Recently published results showed that topical treatment with TLR7 agonist can induce lupus-like disease in wild-type mice. 10 Because our results showed that CCND3 was elevated while miR-15b was decreased in TLR7-activated B cells and B6.MRL-Fas lpr /J lupus mice, we chose the TLR7 agonistinduced lupus-like model. We topically treated wild-type C57BL/6 female mice with IMQ 3 times per week. 10 After treatment for 8 weeks, the IMQ-treated mice showed lupuslike autoimmunity with marked splenomegaly (Figure 7a) . Consistent with B6.MRL-Fas lpr /J mice, IMQ-treated mice showed significant B-cell expansion (Supplementary Figure 2b) . Spleens from IMQ-treated mice also showed spontaneous Band T-cell activation and higher percentages of GC B cells and plasma B cells (Figure 7b-d) . Glomerulonephritis also developed in IMQ-treated mice as indicated by HE staining (Figure 7e ). Real-time PCR was carried out to quantify and compare the expression levels of CCND3 and miR-15b in B cells between female C57BL/6 mice treated with IMQ and control mice. The real-time PCR results showed that there were significantly lower miR-15b and higher CCND3 expression levels in spleen B cells of the mice treated with IMQ than in control mice as well as that the expression level of miR-15b negatively correlated with the level of CCND3 (Figure 7f ). Furthermore, we sorted GC B cells from IMQ-treated mice and non-GC B cells from both IMQtreated mice and the control mice, and the sorting efficiency is shown in Supplementary Figure 3 . The expression levels of CCND3 and miR-15b in GC B cells and non-GC B cells in control mice and IMQ-treated mice were determined (Figure 7g) . The results showed that CCND3 is more highly expressed in IMQ-treated GC B cells and non-GC B cells than in control non-GC cells. However, the expression level of miR-15b was opposite of the expression level of CCND3. Collectively, these data suggest that extrinsic factor TLR7 ligands may lead the abnormality of B cells in SLE.
DISCUSSION
Multiple studies have supported the role of CCND3 in the development and differentiation of B cells and other normal cells, in addition to its basic role in cell cycle regulation and proliferation. 8, 11, 38, 39 However, the study of CCND3 regulation in B cells is yet to be fully understood. In this study, we first found that elevated CCND3 was associated with SLE based on gene profiling analysis. Next, we confirmed this phenomenon in SLE patients and typical B6.MRL-Fas lpr /J lupus mice. We further showed that the activation of TLR7 significantly induced CCND3 expression by decreasing miR-15b expression both in vitro and in vivo. Transfection and a luciferase experiment also showed that miR-15b directly targets the 39-UTR of CCND3. These data provide a novel mechanism regarding the extrinsic factors activating TLR7 to regulate the CCND3 expression, which leads to B-cell abnormity.
Patterns of gene expression in diseases and developmental processes could be assessed using gene expression profiling and microarray analysis. Several gene expression studies have contributed to the discovery of genes related to SLE, especially those studies focused on gene transcripts in T cells and B cells. 33, 40, 41 In this study, we found that most DEGs were enriched in cell cycle pathways in SLE B cells. In accordance with our analysis, the publicly available datasets for the SLE transcriptome also revealed that significant pathways of overexpressed genes are related to the cell cycle. 42 Moreover, we found that CCND3 was elevated in active SLE. CCND3 is a key gene in B-cell development and differentiation, and there are many important activated signaling pathways that contribute to the abnormality of B cells in SLE patients, including IFNa, the BCR signaling pathway and the TLR7 pathway. 18, 34, 35 In this study, we found that other than the two other signaling pathways, only the activation of TLR7 increased the expression of CCND3. Thus, it is necessary for us to uncover the molecular mechanism of the TLR7 pathway in elevating CCND3 in active SLE. miRNAs are important factors during the pathogenesis of SLE. 30 Our findings revealed that miR-15a, miR-15b, and miR-16 were decreased in the PBMC of active SLE patients. All three of these miRNAs belong to the miR-15 family, which is predicted to target the expression of CCND3. We thus chose miR15b as the modulator of CCND3 because the expression level of miR-15b was the highest of the miR-15 family in B cells and the expression of miR-15b decreased significantly after treatment with R848. Moreover, other studies reported that miR-15b was elevated in SLE patients' kidneys and plasma. 43, 44 In our study, we determined for the first time that miR-15b was downregulated in spleen B cells of lupus-like mice. Luciferase and transient overexpression experiments also confirmed that CCND3 is a direct target of miR-15b.
The activation of TLR7 increased the expression of CCND3 while simultaneously decreasing the expression of miR-15b in vitro. Until this point, it was unclear whether these phenomena exist in the lupus-like model. Using a lupus-like model induced by the topical treatment of B6 mice with IMQ, we showed that CCND3 was significantly elevated, while miR-15b was decreased in the spleen B cells of the lupus-like mice. Of note, previous studies reported that GC censorship of autoreactive B cells was defective in human SLE, and the lupus model mice form GCs spontaneously. 3, 4 Our data showed the activation of TLR7 also increased the percentage of GC formation and PCs in mice spleens. In addition, it was reported that expanded PCs, which were generated through GCs in both the peripheral and bone marrow in SLE patients, 45, 46 are responsible for the production of an array of autoantibodies against soluble and cellular constituents that are most commonly nuclear antigens. 47 Consistent with previous reports, the expression of CCND3 is significantly higher in GC B cells than in non-GC B cells, 7, 8 and the expression of miR-15b in IMQ-treated GC B cells is significantly lower than IMQ-treated and wild-type non-GC B cells. The different expression levels and functions of CCND3 in different B-cell subsets indicated that CCND3 plays different roles in different stages and contexts, and that even the same type of cells may express different level of genes under different circumstances. Our results suggest that TLR7 may boost GC formation through miR-15b regulating CCND3 to result in increased plasma and memory B cells in SLE patients. However, future studies are needed to determine whether miR-15b is a key player in GC formation. In addition, our results and others 48, 49 have shown that B cells were expanded in both B6.MRL-Fas lpr /J and IMQ-induced lupus-like mice. Because it was reported that CCND3 is one of the cyclins promoting the G1/S phase transition, it is reasonable to infer that TLR7 stimulates B-cell proliferation by increasing CCND3 expression.
In summary, we found elevated CCND3 and decreased miR15b in B cells from SLE patients and lupus-like mice. Moreover, activation of TLR7 decreased miR-15b and increased CCND3 in mouse B cells in vitro. Therefore, CCND3 is a direct target of miR-15b. Furthermore, we confirmed that there were significantly increased CCND3 and decreased miR-15b in B cells from the lupus-like mouse model established by the topical treatment of C57BL/6 (B6) mice with the TLR-7 agonist. Our data revealed that activation of TLR7 increases CCND3 expression by downregulating miR-15b in B cells; thus, suggesting that extrinsic factor-induced CCND3 expression may contributes to the abnormality of B cells in SLE.
